

<i>Short Name</i>	<i>Comments</i>	<i>Type</i>	<i>Investigator</i>	<i>Contact</i>
<i>Disease site specific</i>				
<i>Staging, DCIS, Stage 0, Stage I, Stage 2</i>				
Alliance A011104	Preoperative Breast MRI on Surgical Outcomes, Cost, and Quality of Life. Stage I-II; ER neg/PR neg & HER-2 neg breast OR ER neg/PR neg & HER-2 positive tumors For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
CCTG Ma.39	A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
<i>Surgical/ Radiation</i>				
None				
<i>Neoadjuvant</i>				
NSABP B-51	Any ER/PR/HER2; NEOADJUVANT/ Staging: T1-3; Treatment: RT for Patients Who Convert to Path Negative Nodes After Neoadjuvant Chemo and Surgery For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A011202	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
MA39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

Adjuvant Trials

PVB VS PNB	Paravertebral Block Versus Pectoral Nerve Block for Analgesia Following Mastectomy	Treatment	Melnik, Marianne	Marianne Morrissey cancer.research@spectrumhealth.org (616) 486-8500
<p><i>The purpose of this study is to compare two standard methods of pain control management for patients undergoing breast surgery.</i></p>				
NRG BR003	TRIPLE NEGATIVE; Adjuvant; HIGH RISK NODE(-)or NODE(+) / Invasive; A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NSABP B-55	TRIPLE NEGATIVE: BRCA+; Adjuvant; High Risk/ Treatment: <u>Olaparib vs Placebo</u> For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
A011502	A Randomized Phase III Double-Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer; the Aspirin for Breast Cancer Study (ABC Study) For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
NRG CC004	Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer For More Information	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org

S1418	TRIPLE NEGATIVE: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EA1131	TRIPLE NEGATIVE; Adjuvant; BASAL-LIKE Breast Cancer; Phase III Post-Operative; Platinum Based Chemotherapy vs Observation in Patients with Residual following Neoadjuvant Chemotherapy	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
SWOG S1207	ER/PR(+) & HER2-; Adjuvant; Stage I-III; Oncotype Testing Required for Patients with < 4 Positive Lymph Nodes. Treatment: Endocrine Therapy + <u>Everolimus/Placebo</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
CTSU E1Z11	BREAST - ER/PR+; Any HER2; Adjuvant / Stage I - III Adenocarcinoma. Treatment: Anastrozole. <u>Only the Asian and Native Hawaiian/Pacific Islanders cohorts remain open to accrual</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
Stage IIIC, Locally advanced and Stage IV				
HER2-				
CTSU E2112	ER/PR+; Her2-; Stage IIIC or IV; Treatment: Endocrine Therapy plus <u>Entinostat/Placebo</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				

ACCRU RU011201I	Any ER/PR; HER2- ; Stage IIIC or IV; Not Amenable to Local Therapy. Treatment: <u>Eribulin</u> vs Paclitaxel	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
WF97116	A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
S1416	Phase II Rancomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
S1703	Radomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Postive Breast Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
HER2+				
RTOG 1119	Any ER/PR; Her2+; Metastatic; BRAIN METS. Treatment WBRT +/- <u>Lapatinib</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
AFT-38 "Patina"	A randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2 - Positive Metastatic Breast Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			

S1501	Prospect Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
-------	---	-----------	---	---

[For More Information](#)

BRCA +

None

Any ER/PR/HER2

SCRI BRE 203	Any ER/PR/HER2; METASTATIC/ Stage IV Must be AR+ and Fit Into One of These: A. ER-/PR-/Her2-/AR+ With 1-3 Previous Treatment for Metastatic Disease B Postmenopausal ER+ and/or PR+/AR + Refractory MCB With Progression After 1-3 Hormonal Treatments. Treatment: <u>Orteronel</u>	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
--------------	--	-----------	---	---

[For More Information](#)

Breast only symptom management

S1501	Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her-2+ Breast Cancer, Phase III	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
-------	--	-----------	---	---

[For More Information](#)

Protocols that are NOT disease site specific

Treatment

Alexion ALXN6000-ONC-102	Alexion Protocol ALXN6000-ONC-102: A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients with Advanced Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
-----------------------------	--	-----------	---	---------------------------------

	A Phase 1 Study of Oral LOXO-292 in Adult Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) and Other Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients with Advanced Solid Tumors or Lymphomas	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
	A Phase 1a/2a Cohort Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1, in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
ALEXO AT148001	Alexo Protocol AT148001: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
BGB-290	A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

	A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
SCI-CD47-001	First-in-Human Phase I Dose Escalation Trial of HU5F9-G4 in Patients with Advanced Solid Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
MK-4280-001	A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
LZM009-001	A First-in-Human, Multicenter, Open-label, Phase 1 Dose Escalation Study of LZM009 in Subjects with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
ASN002	A Phase I/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
20150195 AMG 820	A Phase Ib/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination with Pembrolizumab in Select Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
R3767-ONC- 1613	A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1-mAb) in Patients with Advanced Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

CP-MGA012-01	A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
MK-4820	A Phase 1 Trial of MK-4820 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
ASN003-101	A Phase I, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
MK-8353-013	A Phase 1b Study to Evaluate the Safety and Tolerability of MK-8353 in Combination with Pembrolizumab in Patients with Advanced Malignancies	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
5F9004	A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CP-MGA012-01	A Phase 1 Study of the Safety, tolerability, and Pharmacokinetics of MGA012 in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
CVM-001	A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients with Advanced Cancer	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
APX_CLN_0011	A Phase 1 Study of APX3330 in Patients with Advanced Solid Tumors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554

CPI-1205-202	A Phase 1 Study of CPI-1205 with Ipilimumab or Pembrolizumab in Patients with Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 with Ipilimumab or Pembrolizumab in Selected Tumor Types Previously Treated with PD-1 or PD-L1 Inhibitors	Treatment	START Midwest Investigators	START Midwest (616) 954-5554
NRG CC003	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
NRG CC001	A Randomized Phase III Trial of Memantine and Whole Brain Radiotherapy with or without Hippocampal Avoidance in Patients with Brain Metastases	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
A071401	Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
<i>Molecular Profiling</i>				
QOL Multisite EAQ-152	EAQ-152 - (COMET MATCH) - A randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			

EAY131 - E	Tumors Having EGFR T790M Mutations (Except NSCLC) or Rare Activating Mutations of EGFR; Treatment: <u>AZD9291</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - F	Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations; Treatment: <u>Crizotinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - G	ROS1 Translocations (Other Than Patients with NSCLC); Treatment: <u>Crizotinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - H	Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer); Treatment: <u>Dabrafenib</u> and <u>Trametinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - J	<u>Trametinib</u> and <u>Pertuzumab</u> (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				

EAY131 - L	Phase II Study of MLN0128 (<u>TAK-228</u>) in Patients with Tumors with mTOR Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - M	Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - R	BRAF Fusions, or Non-V600E, Non-V600K BRAF Mutations; Treatment: <u>Trametinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - S1	<u>Trametinib</u> in Patients with Tumors with NF1 Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - S2	<u>Trametinib</u> in Patients with Tumors with GNAQ or GNA 11 Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			
EAY131 - T	Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations; Treatment: <u>GDC-0449 (vismodegib)</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
	For More Information			

EAY131 - V	Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) Treatment: <u>Sunitinib</u>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - W	Phase II Study of <u>AZD4547</u> in Patients with Tumors with Aberrations in the FGFR Pathway	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - X	<u>Dasatinib</u> in Patients with Tumors with DDR2 Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Y	<u>AZD5363</u> in Patients with Tumors with AKT Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1A	<u>Binimetinib</u> in Patients with Tumors (Other than Melanoma) with NRAS Mutations	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1B	MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				

EAY131 - Z1D	<i>Nivolumab</i> in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1E	Testing <i>LOXO-101</i> as Potentially Targeted Treatment in Cancers with NTRK Genetic Changes		CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
EAY131 - Z1I	Testing <i>AZD1775</i> as a Possible Treatment in People who have Cancer with BRCA Mutations		CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
ASCO TAPUR	Targeted Agent and Profiling Utilization Registry Study. <i>All drugs provided</i>	Molecular Profiling	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				
<i>Biorepository</i>				
NCI PDM 9846	Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)	Biobanking	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
For More Information				

SHARE	The Spectrum Health Universal Biorepository Provides a Robust, Diverse Offering of High, Quality Research and Potential Diagnostic Samples Associated with Relevant De-identified Clinical Data to Investigators	Biobanking	Cottingham, Sandra	Spectrum Health Biorepository david.chesla@spectrumhealth.org (616) 267-2629
--------------	---	------------	--------------------	---

This study will collect high-quality biologic specimens including tumor/diseased tissue, matched normal tissue, bodily fluids, and correlating health information from patients with the diagnosis of neoplasm or other conditions and related data for use in laboratory research.

Assessment/ Education

URCC 13059 GAP-70	Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy for Advanced Cancer: Reducing Chemotherapy Toxicity in Older Adults	Other	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
------------------------------	---	-------	---	---

[For More Information](#)

Symptom Management

S1415CD	A Pragmatic Trial To Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
----------------	--	--------------------	---	---

[For More Information](#)

URCC 04040 YOCAS	A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors	Symptom Management	CRCWM Physician Investigators	CRCWM (616) 391-1230 www.crcwm.org
-----------------------------	---	--------------------	---	---

[For More Information](#)

URCC 16070 Treatment of Refractory Nausea

Symptom [CRCWM](#) CRCWM
Management [Physician](#) (616) 391-1230
 [Investigators](#) www.crcwm.org

[For More Information](#)